Category

Pharmaceutical 4382 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Johnson and Johnson, Ethicon found guilty in transvaginal mesh case; $13.5 million verdict

2012-TVM-serious-complications

Yesterday a verdict was reached on the second case to go to trial in the Philadelphia mass tort program against transvaginal mesh manufacturers. A jury of eight women and four men found in favor of plaintiff Sharon Carlino, who alleged that Johnson and Johnson unit Ethicon’s transvaginal tape product, known as TVT, was negligently designed and her physician was not adequately warned of its risks. The company faces $10 million in punitive damages, $3.5 million in compensatory damages, and another $250,000 to Carlino’s husband for loss of consortium, totaling a $13.5 million verdict. Carlino received the TVT implant in 2005 to ... Read More

Dialysis giant Fresenius urges judge to toss GranuFlo, NaturaLyte lawsuits

dialysis

Fresenius USA, the world’s largest provider of dialysis services and products, pressed a federal judge to throw out hundreds of Massachusetts and Mississippi lawsuits consolidated in a multidistrict litigation (MDL) alleging the company’s dialysis products GranuFlo and NaturaLyte caused patients’ hearts to stop beating. Fresenius’ motion included 169 cases in Massachusetts and 61 in Mississippi. The company contends that the Massachusetts cases were filed more than three years after May 25, 2012 – the date the Food and Drug Administration (FDA) issued a safety warning regarding the products. Fresenius claims the Mississippi cases involved injuries that occurred after May 25, ... Read More

Arianna Huffington suggests you try sleep instead of Viagra

viagra

Arianna Huffington, co-founder and editor-in-chief of the Huffington Post, has had plenty to say about the benefits of sleep over the last nine years, but her most recent claim is particularly rousing. She specifically touts sleep as a free alternative to Viagra in her new book The Sleep Revolution: Transforming Your Life, One Night at a Time, which will be in stores in April. Huffington says she learned the value of resting, very personally, in 2007, when she broke a cheekbone after collapsing from exhaustion. Since then she’s changed her own life, the lives of her employees, and she’s gone on ... Read More

Lawyers seek resolution for transvaginal mesh cases, request move out of MDL

transvaginal mesh

Manufacturers of transvaginal mesh used to treat pelvic organ prolapse and stress urinary incontinence are being sued by tens of thousands of women who claim defective mesh caused internal injuries and left many in constant pain. Since the U.S. Food and Drug Administration (FDA) reclassified transvaginal mesh as a high-risk device earlier this year, acknowledging more than 1,500 reports of problems, these numbers are only likely to increase. According to the FDA, reported complications from the transvaginal placement of the surgical mesh include erosion of the mesh into the vaginal tissue, organ perforation, pain, infection, painful intercourse, and urinary and fecal ... Read More

Are women interested in so-called ‘female Viagra’? Is it safe?

Addyi - image courtesy Fox13Now news

In August 2015, the FDA approved the first medication designed specifically to target sexual dysfunction in women. Addyi (flibanserin) was heralded as the “female Viagra” by the media and featured in Time, Science, CNN, and The Huffington Post, to name a few major news sources that ran articles about “the little pink pill.” Addyi is approved for women with hypoactive sexual desire disorder, or HSDD, a libido-diminishing condition that affects up to 10 percent of women in the U.S. In spite of its catchy nickname, the drug works very differently from Viagra, which is designed to enhance physical performance. Addyi, originally ... Read More

Design flaws uncovered with more DePuy metal hip implants

DePuy-ASR-hip-recall

Design defects with metal-on-metal hip implants made by Johnson & Johnson subsidiary DePuy Orthopaedics are in the spotlight again, this time for “size” issues that are allegedly causing pain and injuries, according to an investigation by The Telegraph. The company says that there was an “error in the measuring techniques” with its metal hip implants manufactured at a DePuy plant in Yorkshire, United Kingdom, and that this design flaw could contribute to adverse events experienced by patients. The company said it removed the equipment causing the problems, though it did not say when it discovered the problem or how it ... Read More

FDA chief nominee Califf faces tough opposition from senators

fda-logo

Dr. Robert Califf’s long-term, significant ties to the pharmaceutical industry prove he would be soft on drug companies pushing new opioid painkillers which, in turn, would worsen the country’s prescription drug abuse epidemic, and for this reason, Califf is unacceptable choice to head the Food and Drug Administration (FDA), said Sen. Joe Manchin, D-W.Va. in a written statement. Manchin added he would filibuster the nomination, using that time to read letters from West Virginia families affected by opioid abuse. Califf currently serves as the FDA’s deputy commissioner for medical products and tobacco. His 2014 financial disclosures revealed he had been ... Read More

Should our DNA be used for corporate profit? Human Rights Committee reviews future of Canadian genetic testing

DNA_orbit_animated_static_thumb

According to CBC News thousands of Canadians are still opting out of genetic testing that could give them valuable information to possibly reduce risks for debilitating or life-threatening illnesses in their own lives, or knowledge that could inform their children’s medical futures. With Canada being the only G7 country with no form of protection against genetic discrimination, its citizens have reason to fear that such tests will be reported to insurance companies, raising premiums or hurting their chances of being eligible for coverage. In some cases, they fear employers requesting this information and that it might compromise their careers. A senate ... Read More

Diabetes drug study prompts change in what doctors prescribe

Invokana

Three quarters of physicians say they are prescribing more of the type 2 diabetes drug Jardiance to their patients after news that the drug significantly reduced the risk of death in diabetic patients, according to an online poll conducted by Medscape Medical News. Jardiance, manufactured by Boehringer Ingelheim and Eli Lily and Co., is in a class of newer diabetes drugs known as SGLT2 inhibitors. Other brand-name drugs in this class include Invokana and Invokamet, both made by Johnson & Johnson subsidiary Janssen Pharmaceuticals. The poll was prompted by a study published last fall in the New England Journal of ... Read More

Johnson and Johnson fights to keep Cherokee Nation’s Risperdal case in federal court

risperdal

Johnson & Johnson and its subsidiary Janssen Pharmaceuticals are asking an Oklahoma federal judge to keep in federal court a lawsuit filed against the companies by the Cherokee Nation over undisclosed side effects with its antipsychotic drug Risperdal. The drug companies claim that the rightful plaintiff in the case is not the Cherokee Nation, but a holding company for the tribal businesses, and that the case should remain in federal court on diversity grounds. The Cherokee Nation originally filed the lawsuit in April 2015 in Oklahoma’s Sequoyah County Court seeking restitution for Risperdal the tribe had purchased under the impression ... Read More